Home Blog Page 421

CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

Key Highlights:

  • Excellent Safety Profile:  As of mid-March 2026, 113 heavily pretreated patients with solid tumors have been enrolled in the Phase I trial of CS2009, with a median follow-up of approximately 6 months. The more mature data continue to show a favorable safety profile, with 23% incidence of Grade ≥3 Treatment-Related Adverse Events (TRAEs). No excessive toxicities that typically occurred in combination therapies containing CTLA-4 and PD-(L)1 were observed, and the incidence of Grade ≥3 VEGF-related AEs was low.
  • Compelling Efficacy in Lung Cancer: CS2009 monotherapy demonstrates potentially transformative Phase I/II efficacy in Non-Small Cell Lung Cancer (NSCLC). In first-line NSCLC (PD-L1 tumor proportion score [TPS]≥50%), the overall response rate (ORR) reached 90%, with a disease control rate (DCR) of 100%. In AGA-negative, later-line NSCLC, ORR reached 25%.
  • Broad Antitumor Potential, Including in “Cold Tumors”: CS2009 monotherapy also demonstrates potent antitumor activity in later-line “cold” tumors that are not sensitive to PD-(L)1 mAb. An ORR of 40% was observed in patients with non-clear cell renal cell carcinoma (nccRCC), and an ORR of 33.3% in soft tissue sarcoma (STS), demonstrating its broad-spectrum therapeutic potential across multiple tumor types.
  • Accelerated Global Phase III Development Plan: The company plans to initiate the first wave of Phase III global multi-regional clinical trials (MRCT) for CS2009 by the end of 2026, targeting indications including NSCLC, colorectal cancer (CRC), and small cell lung cancer (SCLC).
  • Data Presentation Plan: Updated Phase I and Phase II clinical data for CS2009 are expected to be disclosed at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and/or the European Society for Medical Oncology (ESMO) Congress.

SUZHOU, China, March 26, 2026 /PRNewswire/ — CStone Pharmaceuticals (HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapeutics for oncology, immunology, inflammation, and other key disease areas, today announced encouraging clinical progress for CS2009, a novel PD-1/VEGF/CTLA-4 trispecific antibody.

Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, stated, “Based on the latest clinical data for CS2009, we are confident in its potential to transform treatment paradigms across a broad spectrum of tumor types. Driven by its unique molecular design, CS2009 offers key mechanistic differentiation. To date, approximately 200 patients have been enrolled, demonstrating an outstanding safety profile with no observation of the severe toxicities commonly associated with combination regimens containing CTLA-4 and PD-(L)1 inhibitors.

In terms of efficacy, CS2009 has delivered compelling results across multiple indications: as a monotherapy in first-line NSCLC, it achieved an ORR of 90% in patients with PD-L1 TPS ≥ 50%. Significant benefits were also observed in historically difficult-to-treat ‘cold tumors’, including IO-pretreated advanced NSCLC, non-clear cell renal cell carcinoma (nccRCC), and soft tissue sarcoma (STS). Furthermore, Phase II studies evaluating CS2009 in combination with standard chemotherapy for first-line NSCLC, CRC, and other indications have yielded high objective response rates.

We look forward to presenting additional Phase I and Phase II data at this year’s ASCO and/or ESMO congresses. Currently, we are engaged in advanced partnership discussions with several global multinational pharmaceutical companies and aim to initiate multiple Phase III MRCT by the end of 2026.”

Rapid Patient Enrollment with Phase I/II Data Supporting Favorable Safety and Efficacy

The global multi-center Phase I/II clinical trial for CS2009 is actively ongoing in Australia and China, and its Investigational New Drug (IND) application for Phase II has been approved by the U.S. Food and Drug Administration (FDA). As of mid-March 2026, a total of 113 patients with advanced solid tumors have been enrolled in Phase I, with a median follow-up of approximately six months. 85 patients have been enrolled in Phase II.

1. Phase I Data Reinforces an Excellent Safety Profile:

  • CS2009 demonstrates a favorable safety and tolerability profile across all six dose levels evaluated, with no dose-limiting toxicities (DLTs) observed and the maximum tolerated dose (MTD) not reached.
  • The incidence of Grade ≥3 TRAEs was 23%; Grade ≥3 immune-related adverse events (irAEs) was 12.4%; and Grade ≥3 VEGF-related TRAEs was 4.4%. No excessive toxicities that typically occurred in combination therapies containing CTLA-4 and PD-(L)1 were observed.

2. Broad Antitumor Activity Observed in Heavily-Pretreated NSCLC and “Cold Tumors”:
Antitumor activity was observed across all dose levels, with robust efficacy signals in multiple tumor types.

  • At the 30 mg/kg, Q3W, CS2009 monotherapy achieved an ORR of 25% (6/24) and a DCR of 58.3% (14/24) in AGA-negative, later-line NSCLC patients.
  • Across dose levels, CS2009 monotherapy resulted in an ORR of 40% and a DCR of 100% in patients with nccRCC (n=5).
  • Across dose levels, CS2009 monotherapy resulted in an ORR of 33.3% and a DCR of 66.7% in patients with STS (n=9).

Phase II Data Reveal Transformative Potential of CS2009: 90% ORR with Monotherapy in First-Line NSCLC and Excellent Tolerability in Combination Regimens for First-Line NSCLC and CRC

The global multi-center Phase II clinical trial employs a multi-cohort parallel expansion design to evaluate the efficacy and safety of CS2009 monotherapy and combination therapy across 15 cohorts in 9 solid tumor types, including NSCLC, CRC, extensive-stage small cell lung cancer (ES-SCLC), cervical cancer (CC), gastric or gastroesophageal junction cancer (GC/GEJC), esophageal squamous cell carcinoma (ESCC), platinum-resistant ovarian cancer (PROC), triple-negative breast cancer (TNBC), and hepatocellular carcinoma (HCC).

1. Monotherapy Shows Striking Efficacy in First-line NSCLC:
CS2009 monotherapy (20 mg/30 mg, Q3W) achieved an ORR of 90% (9/10) and a DCR of 100% (10/10) in first-line NSCLC patients with PD-L1 TPS≥50% (n=10).

2. Combination Therapies Demonstrate Favorable Tolerability and Promising Efficacy
Safety data from multiple cohorts of CS2009 combined with standard chemotherapy showed that the combinations were well-tolerated across tumor types, with CS2009 without increasing the incidence or severity of chemotherapy-related adverse events. Initial potent antitumor activity was observed with combination treatment in first-line NSCLC and first-line CRC.

Efficient and Clearly-Defined Global Development Strategy

CStone plans to initiate the first set of Phase III global MRCTs for CS2009 by the end of 2026, focusing on indications including NSCLC, CRC, and SCLC.

Additional Phase I and Phase II clinical data for CS2009 are expected to be presented at the 2026 ASCO and/or ESMO Annual Meetings.

About CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

CS2009, an innovative trispecific antibody designed and developed by CStone, with the potential to be first- or best-in-class. It combines three clinically validated targets—PD-1, VEGFA, and CTLA-4—and exerts multidimensional antitumor effects through synergistic actions. Specifically, anti-PD-1 activity reverses T cell exhaustion, anti-CTLA-4 activity promotes T cell activation and proliferation, while anti-VEGFA activity blocks tumor angiogenesis and improves the tumor micro-environment (TME). In the TME, anti-PD-1 and anti-CTLA-4 activities are significantly enhanced by crosslinking with VEGFA. Meanwhile, CS2009 preferentially blocks PD-1 and CTLA-4 on double-positive tumor-infiltrating T cells while minimizing interference with CTLA-4 regulation in peripheral T cells.

About CStone Pharmaceuticals

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 21 new drug applications covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit: www.cstonepharma.com.

 

C-Ray Therapeutics and SHINE Technologies Enter Strategic Partnership for Exclusive Distribution of No-Carrier-Added Lu-177 in Mainland China

CHENGDU, China and JANESVILLE, Wis., March 26, 2026 /PRNewswire/ — C-Ray Therapeutics (Chengdu, China), a global radiopharmaceutical CRDMO, today announced the execution of a Master Radioisotope Supply Agreement with SHINE Technologies, LLC (Janesville, Wisconsin, USA), establishing a long-term, GMP-compliant supply of no-carrier-added lutetium-177 (n.c.a. Lu-177) and granting C-Ray exclusive distribution rights for this critical medical isotope across mainland China — excluding certain pre-existing SHINE partnerships.

Under the agreement, C-Ray will serve as SHINE’s exclusive distribution partner in mainland China, supplying n.c.a. Lu-177 to Chinese radiopharmaceutical developers, biotechnology companies, and healthcare institutions. C-Ray will leverage its integrated, 28,000-square-meter Chengdu facility to provide downstream services including isotope conjugation, fill-and-finish, and quality control — delivering an end-to-end, ready-to-use isotope solution that substantially lowers the barrier for domestic companies to access internationally benchmarked radioisotope supply.

A Critical Isotope, a Strategic Supply

Lu-177 is among the most widely used therapeutic radioisotopes in targeted radiopharmaceutical therapy (TRT) globally, with approved and investigational applications across prostate cancer, neuroendocrine tumors (NETs), and a growing range of oncology indications. Its favorable physical half-life, beta emission energy, and co-imaging capability have made it the cornerstone isotope of the RDC field.

Supply security has long been a practical constraint on pipeline development in China. This partnership addresses that gap directly: SHINE’s Cassiopeia facility — one of North America’s largest n.c.a. Lu-177 production sites — will supply C-Ray under terms meeting both Chinese and U.S. regulatory standards, while C-Ray’s on-the-ground infrastructure ensures reliable last-mile delivery to clients across mainland China.

Leadership Perspectives

“This partnership is a significant step in C-Ray’s strategic supply diversification. Stable, multi-source isotope access is a core competitive advantage for us and our clients. Building on our leadership in Ac-225 supply, securing a reliable, high-quality source of n.c.a. Lu-177 — along with exclusive distribution rights — directly strengthens our clients’ pipeline continuity and reinforces our commitment to building a resilient radiopharmaceutical ecosystem in China. With our integrated platform and deep project management experience, we are confident in our ability to translate premium isotope supply into real patient outcomes and accelerated clinical translation across the industry.”
— Haitao Qiao, General Manager, C-Ray Therapeutics

“We are pleased to partner with C-Ray. This partnership reflects SHINE’s ability to serve growing demand for n.c.a. Lu-177 in China while maintaining strong supply for customers in the U.S. and other global markets. By combining C-Ray’s integrated development and manufacturing platform with our large-scale isotope production, we can help advance pipeline innovation and expand patient access to life-saving targeted radioligand therapies.”
— Greg Piefer, Founder and CEO, SHINE Technologies

About SHINE Technologies

Headquartered in Janesville, Wisconsin, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, cost-efficiency and environmental responsibility. SHINE has successfully commercialized fusion across multiple applications, including neutron testing markets such as neutron radiography, radiation-effects testing and fusion material research. It has commercialized and is scaling its proprietary medical isotope production processes, supplying high-quality radioisotopes essential for procedures including diagnosing heart disease and cancer as well as cancer therapy.

Beyond these applications, SHINE is pioneering nuclear waste recycling to make nuclear energy more sustainable. Its long-term purpose is to change the way humans make energy by commercializing fusion energy. Unlike other fusion companies, SHINE takes a commercially driven path mirroring successful deep-tech industries. Through this visionary approach, SHINE is advancing technology, healthcare, and sustainable energy, making a lasting impact across multiple sectors. Learn more at www.shinefusion.com.

About C-Ray Therapeutics

C-Ray Therapeutics is a global CRDMO providing end-to-end radiopharmaceutical development services — from target validation and preclinical evaluation to IND-enabling studies, clinical supply, and commercial-scale cGMP manufacturing. Operating from its 28,000-square-meter Chengdu facility under China’s Class A Radiation Safety License, C-Ray supports 30+ radioisotopes and has delivered 70+ projects spanning diagnostic and therapeutic programs, including 5 programs at IND or IND-enabling stage, 5 in clinical supply, and 2 in Phase III clinical trials. For more information, visit www.c-raytherapeutics.com 

 

Another Month, Another Milestone: Bybit Earn’s Mantle Vault More than Doubles AUM in First Quarter of 2026

DUBAI, UAE, March 26, 2026 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, announced another landmark achievement for Mantle Vault on Bybit On-Chain Earn on March 26, 2026. The game-changing yield-generating product launched in partnership with Mantle and Cian, has reached US$200 million in Assets Under Management (AUM), demonstrating explosive adoption and market demand for structured stablecoin yield solutions.

This milestone represents extraordinary momentum: the product has grown from its December 22, 2025 launch through a remarkable trajectory, hitting $100 million by early January, and now doubling to $200 million in just 94 days. The sustained growth reflects a fundamental market shift toward sophisticated, low-volatility investment structures during a period of measured macro consolidation.

Mantle Vault offers a unique access point to DeFi yield anchored in smart stablecoin strategies, and readily available on Bybit’s ultra user-friendly CeFi interface, helping users put the search for return on auto pilot.

How Mantle Vault Delivers Consistent Yield

Mantle Vault’s formula combines three key elements to deliver consistent performance:

  • Yield Generation: Users may earn returns through Ethena staking (sUSDe) and leveraged staking of USDT, USDC, and USDe on Aave V3 with potential additional incentives from Bybit and Mantle partnerships.
  • Market-Neutral Strategy: Mantle Vault’s proprietary market-neutral strategies helps minimize volatility exposure, allowing users to isolate yield from price risk, offering a critical advantage during periods of technical consolidation.
  • Smart Contract Security: All assets are secured by audited smart contracts on Aave V3 (Ethereum mainnet), providing institutional-grade custody standards on-chain.

Another Month, Another Milestone: Bybit Earn’s Mantle Vault More than Doubles AUM in First Quarter of 2026
Another Month, Another Milestone: Bybit Earn’s Mantle Vault More than Doubles AUM in First Quarter of 2026

In 2026, sophisticated DeFi products have transitioned from high-yield speculative markets to a more mature, institutional-grade infrastructure with strong fundamentals and market demand. 

The highly flexible product also offers zero subscription fees, and a low entry threshold starting at just 10 USDT or USDC, with most withdrawals processed within 0–3 days.

Terms and conditions apply. Past APR does not guarantee future APR. Returns may change due to Aave market demand, Ethena rewards or gas cost fluctuations. For details on qualification rules, restrictions, and eligibility, users may visit: [Bybit x Mantle x Cian] Introducing Mantle Vault: Stablecoin on-chain yield strategy built for stability, flexibility, and scale

#Bybit / #CryptoArk / #IMakeIt

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

Energy Storage Safety Elevated: Sungrow & TÜV Rheinland White Paper Unveiled

SYDNEY, March 26, 2026 /PRNewswire/ — Sungrow, the global leading PV inverter and energy storage system provider, has launched joint white paper with TÜV Rheinland, an international testing, inspection, and certification organization. Titled “Sungrow Energy Storage White Paper: A Holistic Approach to Safety,” the white paper presents a comprehensive framework designed to address emerging risks in large-scale energy storage deployments and support the industry’s transition toward higher levels of reliability and sustainability.

Sungrow Energy Storage White Paper A Holistic Approach to Safety
Sungrow Energy Storage White Paper A Holistic Approach to Safety

Why Energy Storage Safety Matters More Than Ever
As the global energy transition accelerates, energy storage is becoming a critical pillar of modern power systems, enabling large-scale renewable penetration and enhancing grid flexibility. However, the rapid expansion of the sector has also brought safety challenges into sharper focus. Increasing battery capacities, higher system densities, and the deployment of gigawatt-scale storage plants are significantly raising the complexity of risk management. Traditional single-layer protections and short-term cost-driven approaches are no longer sufficient to address system-level risks, representing a critical constraint on sustainable development. Against this backdrop, the newly released white paper reflects this broader shift toward more comprehensive safety practices.

A Holistic Approach to Safer Energy Storage Systems
At the heart of the white paper is Sungrow’s holistic approach to energy storage safety, which integrates protection across two key dimensions: system architecture and lifecycle management.

At the system level, safety protection extends through the entire technical stack—from battery cells, packs, and racks to system containers, power plants, and ultimately the grid. By moving beyond traditional component-level safety approaches, the framework enables coordinated protection across every layer of an energy storage facility.

Across the lifecycle, safety management begins with simulation-driven design and engineering and continues through verification, manufacturing, operation, maintenance, service, and environmentally responsible decommissioning.

Through this integrated framework—from cells to the grid, and from simulation-driven development to green end-of-life management—safety is embedded into every stage of system development and deployment, ensuring that risks can be anticipated, managed, and mitigated throughout the operational life of an energy storage asset.

Strengthened by Independent Validation
As a co-releasing partner, TÜV Rheinland has endorsed the holistic safety concept. In the foreword, Weichun Li, Senior Vice President of Solar & Commercial Products at TÜV Rheinland Greater China, stated: “Throughout the full product lifecycle—from research and development to manufacturing, deployment, and eventual decommissioning—we apply rigorous, science-based methodologies with a global perspective. This approach not only provides authoritative validation for products but also strengthens the industry’s overall safety framework, facilitating the concurrent advancement of innovation and risk management.

Supporting the Future of Energy Storage
The release of ESS safety white paper reflects a shared commitment by Sungrow and TÜV Rheinland to advancing safer and more reliable energy storage systems worldwide. As the industry continues to scale, a comprehensive approach to safety will be essential to ensuring sustainable growth and unlocking the full value of energy storage.

To learn more about the white paper, please click the link:
https://info-support.sungrowpower.com/market-material/7a636fe1-f545-491a-884c-34be0cdbeaad.pdf

About Sungrow
Sungrow, a global leader in renewable energy technology, has pioneered sustainable power solutions for over 29 years. As of Dec 2025, Sungrow has installed over 1000 GW of power electronic converters worldwide. The company is recognized as the world’s most bankable PV inverter and energy storage company (BloombergNEF). Its innovations power clean energy projects across the globe, supported by a network of 520 service outlets guaranteeing excellent customer experiences. At Sungrow, we’re committed to bridging to a sustainable future through cutting-edge technology and unparalleled service. For more information, please visit: www.sungrowpower.com/en  

CONTACT: Luly Wang, luly.wang@sungrow-hq.com 

VinFast VF 8 Builds Confidence the Long Way With a 10-Year Warranty

A 10-year warranty, mobile support, and charging partnerships position the VF 8 as a long-term bet that feels unusually secure for a new entrant.


DUBAI, UAE – Media OutReach Newswire – 26 March 2026 – When an unfamiliar badge shows up in the crowded Gulf car market, buyers tend to default to caution. For new entrants, that hesitation has to be addressed early, and warranty coverage has become one of the most effective tools for doing so.

Photo.jpg

For example, the upstart VinFast offers the VF 8 with a 10-year or 200,000-km vehicle warranty, paired with a 10-year unlimited-km battery warranty across GCC markets. The scale of that coverage quickly becomes shorthand for durability, removing the question “Will this brand last?” from the customer’s subconscious altogether and replacing it with a more grounded “What happens if something goes wrong over the next decade?” That, at least, is the intention behind the strategy.

Today, many established brands still offer three to five years of basic coverage, with longer terms often limited to specific components or available only through paid extended plans. That gap becomes immediately visible in showroom comparisons, where buyers are weighing not just upfront cost but long-term ownership risk. In markets like the Gulf, where durability and resale value are closely scrutinized, a longer warranty can directly influence perceived value over time.

There is data to support why this approach matters. A 2023 YouGov survey across 18 markets found that 78% of global consumers consider warranty coverage an important factor when buying a car[1]. In the UAE, that figure stands at 77%, reinforcing how central after-sales assurance is to purchase decisions.

From the OEM’s point of view, long warranties are rarely reckless. Modern EV powertrains have fewer moving parts than combustion engines, and catastrophic failures are statistically rare when vehicles are maintained properly. By structuring coverage carefully, manufacturers can advertise large, attention-grabbing numbers while keeping real exposure controlled, with robust quality assurance helping keep issues minimal and manageable.

In the Middle East, VinFast’s after-sales strategy extends beyond the warranty itself, with mobile battery rescue and repair support, alongside 24/7 roadside assistance and five years of free maintenance up to 100,000 km. These are not random additions. They target specific anxieties around EV ownership, particularly in regions where charging infrastructure is still evolving.

Known for its ecosystem thinking, VinFast is also building out its support network in parallel. In the UAE, VinFast recently signed an MoU with PlusX Electric, a DEWA-approved charging provider, to extend support beyond the dealership network. The plan includes portable charging pods, on-demand mobile charging, and emergency roadside charging services. The goal is to reduce downtime and eliminate the awkward scenario of running low on charge far from a plug.

“VinFast is committed to building a long-term and comprehensive EV ecosystem in the UAE—one that gives customers confidence not only in the quality and performance of our electric vehicles, but also in the reliability and accessibility of the supporting infrastructure,” one executive of VinFast Middle East said in a press release.

This layered approach matters because warranties alone don’t solve daily inconveniences. A long-term contract reassures buyers at the point of purchase, but ownership confidence is shaped by what happens on a random Tuesday evening when something goes wrong. Mobile service units, fast parts supply, and integrated charging support close that gap.

Hashtag: #VinFast

The issuer is solely responsible for the content of this announcement.

DIFC elevates Dubai to 7th ranking in Global Financial Centres Index, accelerating towards top 4 global financial hub ambition

DUBAI, UAE, March 26, 2026 /PRNewswire/ — Dubai has recorded its highest ever ranking on the Global Financial Centres Index (GFCI) at seventh place globally underscoring the Emirate’s accelerating rise among the world’s most influential financial hubs and its importance in the global financial system.

DIFC
DIFC

This achievement is pivotal in Dubai’s ambitious goal to become one of the top four global financial centres by 2033, in line with the Dubai Economic Agenda (D33), which aims to solidify the emirate’s status as a global financial, investment and innovation hub.

Dubai’s performance is the highest ranking ever achieved by a financial centre in the Middle East, Africa and South Asia (MEASA), as it remains the only centre from the region to feature in the top 20, underscoring its regional leadership and global competitiveness.

The Emirate’s financial ecosystem is anchored by the continued expansion and global impact of Dubai International Financial Centre (DIFC), which continues to cement its position as a comprehensive financial hub.

The ranking positions Dubai alongside financial hubs including London, New York City and Singapore. Dubai remained one of ten cities in the world to be a global industry leader and ranked the number one financial centre expected to become more significant.

HE Essa Kazim, Governor of DIFC, commented: “Dubai’s remarkable progress in the Global Financial Centres Index is an outstanding milestone that highlights the Emirate’s ambitious vision and expanding influence on the international financial stage. Anchored by DIFC’s world-class infrastructure and forward-looking regulatory environment, we continue to strengthen Dubai’s position as the region’s leading global financial hub, attracting top-tier financial institutions, innovators and talent.”

In recent years, DIFC has experienced record-breaking growth, hosting over 9,000 active companies, including the world’s largest banks, asset managers, hedge funds, insurers, professional services firms, and a workforce of over 50,000.

For the first time, industry respondents ranked Dubai in the top 15 across all evaluated sectors, and as the region’s only city to feature anywhere in this prestigious cluster. Banking is ranked 14th, Finance, Investment Management and Insurance are in the top 10, and FinTech, Government & Regulatory, Professional Services and Trading advanced into the top 5. Dubai is also recognised as the region’s only financial centre among the top ten cities globally competitive for Business Environment, Financial Sector Development, Human Capital and Infrastructure.

 

Sanya 2026 Ticketing System Launched: 118,000 Discounted Tickets on Sale Globally

SANYA, China, March 26, 2026 /PRNewswire/ — On March 23, at the 30-day countdown press conference for the 6th Asian Beach Games Sanya 2026 (“the Games” or “Sanya 2026”), the ticketing system was officially launched. Starting today, 118,000 discounted tickets are available to the public worldwide. People can conveniently purchase tickets for various events through the designated official online channels, getting an early taste of the convenient and smart ticketing services.

The 6th Asian Beach Games Sanya 2026 30-day countdown press conference
The 6th Asian Beach Games Sanya 2026 30-day countdown press conference

As the official online ticketing platform designated by the 6th Asian Beach Games Sanya 2026 Organising Committee (SABGOC), the system includes the official ticketing website and the “6th Asian Beach Games Ticketing” mini-program, offering tickets for the competition events to the global public. The platform integrates functions such as information release, user registration, and online ticket purchasing, aiming to create a convenient, efficient, and personalized ticket-buying experience.

According to Zhang Yue, head of the Ticketing Division in the Marketing Department of the 6th Asian Beach Games Sanya 2026 Executive Committee (SABGEC), “Currently, the public can purchase tickets for events such as 3×3 Basketball, Beach Volleyball, Beach Handball, Sport Climbing, Beach Soccer, Teqball, Wrestling, Jiu Jitsu, Beach Kabaddi, and Beach Athletics through official ticketing channels. Ticket prices range from 30 to 200 yuan, with an average price of 80 yuan.” The Games will feature 10 venues with nearly 10,000 spectator seats available, and approximately 100,000 tickets are planned for sale.

In line with the “Green Games” environmental philosophy, the Games will primarily adopt e-tickets. After completing registration and real-name authentication on the official ticketing platform, the public can select and purchase tickets for their desired sessions and enter the venues by presenting their e-tickets. To accommodate those who may have difficulty using mobile phones, the SABGOC has set up on-site ticket booths at each venue to provide paper ticket sales services, ensuring that everyone who wants to attend can purchase tickets conveniently.

The SABGOC has introduced multiple public-friendly benefits. During the Games, all spectators who purchase tickets can enjoy exclusive discounts at recommended merchants. Additionally, ticket holders can enjoy free bus rides within Sanya’s urban area on the day of the event. With e-tickets as the primary format, on-site ticket booths will open at all venues two days before the start of the competitions to meet the ticketing needs of diverse groups.

Getinge publishes Annual Report for 2025

GOTHENBURG, Sweden, March 26, 2026 /PRNewswire/ — Today, Getinge publishes its Annual Report for 2025, including the Sustainability statement. The year was marked by geopolitical friction and significant cost impacts from tariffs and currency movements, while the company delivered strong underlying profitability, continued regulatory progress, and an ambitious innovation agenda.

Getinge’s 2025 Annual Report summarizes the year’s performance, both financially and in sustainability, and provides an overview of the company’s strategy, targets, and governance. The medtech company’s net sales in 2025 amounted to SEK 35 billion, with organic growth across all business areas. Despite combined headwinds from currency effects and tariffs exceeding SEK 1 billion, the company delivered an unchanged adjusted EBITA margin for the full year, confirming a robust business model and increased operational resilience.

“2025 was a year in which our strategy, global presence, and ways of working were truly tested – and proved their strength. Despite a more complex external environment, we delivered steady results, reached important regulatory milestones, and continued to strengthen our position in our prioritized markets,” says Mattias Perjos, President and CEO at Getinge.

During the year, Getinge made significant progress in quality and regulatory compliance, including the reinstatement of the CE certificate for its intra-aortic ballon pump Cardiosave and several new MDR approvals. At the same time, several new products and solutions were launched within intensive care, surgical workflows, and life science, with a focus on productivity, patient safety, and sustainable use of resources.

Demand for more efficient and sustainable healthcare continues to be driven by demographic changes, resource constraints, and increasing pressure on healthcare systems. Getinge addresses this through a broad offering, close customer collaboration, and an increasing number of solutions that improve workflows and reduce environmental impact.

“Our long-term direction remains unchanged. With a focus on quality, innovation, and close customer partnerships, we continue to build on a strong foundation for profitable growth and long-term value creation,” says Perjos.

Getinge has continued to strengthen its financial position with reduced net debt and strong equity ratio. The Board of Directors proposes a dividend of SEK 4.75 per share for the 2025 financial year.

Getinge’s Annual Report for 2025, including the Sustainability statement, is available at https://www.getinge.com/.

Investor Relations:

David Kördel, Head of Investor Relations
Phone: +46 (0)10 335 0077
Email: david.kordel@getinge.com 

Media contact:

Caroline Örmgård, Head of Media Relations
Phone: +46 (0)10 335 0041
Email: caroline.ormgard@getinge.com

This information is information that Getinge AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 10.00 CET on March 26, 2026.

About Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/getinge/r/getinge-publishes-annual-report-for-2025,c4327032

The following files are available for download: